Eligibility Prostate Cancer NCT01784757

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
written informed consent (ic) obtained.
Descrizione

ID.1

Tipo di dati

boolean

histologically confirmed adenocarcinoma of prostate
Descrizione

ID.2

Tipo di dati

boolean

progressive metastatic disease
Descrizione

ID.3

Tipo di dati

boolean

ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy
Descrizione

ID.4

Tipo di dati

boolean

adequate bone marrow, hepatic and renal function
Descrizione

ID.5

Tipo di dati

boolean

able to swallow the odm-201 whole as a capsule or tablet.
Descrizione

ID.6

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous chemotherapy for prostate cancer.
Descrizione

ID.7

Tipo di dati

boolean

known metastases in the brain.
Descrizione

ID.8

Tipo di dati

boolean

history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
Descrizione

ID.9

Tipo di dati

boolean

known gastrointestinal condition that can significantly affect the absorption of the study treatment.
Descrizione

ID.10

Tipo di dati

boolean

Similar models

Eligibility Prostate Cancer NCT01784757

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
written informed consent (ic) obtained.
boolean
ID.2
Item
histologically confirmed adenocarcinoma of prostate
boolean
ID.3
Item
progressive metastatic disease
boolean
ID.4
Item
ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy
boolean
ID.5
Item
adequate bone marrow, hepatic and renal function
boolean
ID.6
Item
able to swallow the odm-201 whole as a capsule or tablet.
boolean
Item Group
C0680251 (UMLS CUI)
ID.7
Item
previous chemotherapy for prostate cancer.
boolean
ID.8
Item
known metastases in the brain.
boolean
ID.9
Item
history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
boolean
ID.10
Item
known gastrointestinal condition that can significantly affect the absorption of the study treatment.
boolean